ArticleInfluenza and other respiratory viruses2025
Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMonitoring immunity levels nationwide and identifying disparities are important to prepare for future pandemics. However, data regarding changes in the seroprevalence of SARS-CoV-2 and disparities in consecutive epidemic waves using existing surveillance systems are limited.
methodsWe conducted a cross-sectional serosurvey using 11,506 residual serum samples collected from the Korean National Health and Nutrition Examination Survey between January 2021 and December 2022. Antibodies to the SARS-CoV-2 spike (anti-S) protein, indicative of vaccination or past infection of SARS-CoV-2, and nucleocapsid (anti-N) protein, indicating infection, were quantified. Then, we applied post-stratification weighting through the bootstrap resampling based on the age and sex distribution of the South Korean population. We used regression models to identify any disparities in the seropositivity prevalence ratio (PR) across different epidemic waves of SARS-CoV-2 and demographics in the population.
resultsWe identified that the anti-S seropositivity gradually increased after the COVID-19 vaccination rollout, whereas anti-N seropositivity increased after the SARS-CoV-2 Omicron variant was introduced in Korea. Anti-S seropositivity PR was 0.12-0.76 times lower in individuals < 18 years than in elderly individuals ≥ 65 years during Waves 4-5 (July 2021 to June 2022). Anti-N seropositivity PR was 1.25-1.83 times higher in individuals less than 64 years than in elderly individuals during Waves 5-7 (January 2022 to December 2022).
conclusionsOur findings provide insights into the dynamic changes in immunity levels among the Korean population after the COVID-19 vaccine rollout and the introduction of the Omicron variant. Identifying the disparity in seroprevalence in the study population during the pandemic by using the existing surveillance system provides helpful information to develop future pandemic preparedness plans for the population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.